Seaport Therapeutics, Inc. (SPTX) competitors & alternatives
Health Care · NASDAQ
Seaport Therapeutics, Inc. (SPTX)'s top competitors and alternatives — its most similar public companies — include PALISADE BIO INC (PALI), CORBUS PHARMACEUTICALS HOLDINGS IN (CRBP), CULLINAN THERAPEUTICS INC (CGEM), MBX BIOSCIENCES INC (MBX), SAVARA INC (SVRA), Odyssey Therapeutics, Inc. (ODTX), ACLARIS THERAPEUTICS INC (ACRS), IRONWOOD PHARMA INC CLASS A (IRWD), ONCOLOGY INSTITUTE INC (TOI), ALPHA TEKNOVA INC (TKNO), NAUTILUS BIOTECHNOLGY INC (NAUT) and VIRIDIAN THERAPEUTICS ORS INC (VRDN). These are Seaport Therapeutics, Inc.'s closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top SPTX competitors & alternatives
-
PALISADE BIO INCPALIHealth Care
A clinical-stage biotech developing PALI-2108, a licensed small-molecule candidate in Phase 1 trials, with a capital-dependent model dependent on licensing…
$1.90 (as of 2026-07-22) · market cap $331M
-
CORBUS PHARMACEUTICALS HOLDINGS INCRBPHealth Care
Clinical-stage biopharmaceutical company developing next-generation antibody drug conjugates for oncology and a CB1 receptor inverse agonist for obesity.
$8.84 (as of 2026-07-22) · market cap $163M
-
CULLINAN THERAPEUTICS INCCGEMHealth Care
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing targeted, innovative therapies for cancer and autoimmune diseases.
$17.65 (as of 2026-07-22) · market cap $1.1B
-
MBX BIOSCIENCES INCMBXHealth Care
A clinical-stage biopharmaceutical company leveraging a proprietary platform to optimize drug candidate properties and develop therapies across multiple…
$58.30 (as of 2026-07-22) · market cap $2.9B
-
SAVARA INCSVRAHealth Care
Savara is a clinical-stage biopharmaceutical company dedicated to developing innovative inhalable therapies for rare respiratory diseases.
$5.65 (as of 2026-07-22) · market cap $1.2B
-
Odyssey Therapeutics, Inc.ODTXHealth Care
A clinical-stage biotechnology company developing a pipeline of novel small molecule and protein therapeutic candidates.
$18.61 (as of 2026-07-22) · market cap $865M
-
ACLARIS THERAPEUTICS INCACRSHealth Care
Aclaris Therapeutics is a clinical-stage biopharmaceutical firm developing a pipeline of novel treatments for immuno-inflammatory diseases through a strategy…
$5.62 (as of 2026-07-22) · market cap $778M
-
IRONWOOD PHARMA INC CLASS AIRWDHealth Care
Ironwood Pharmaceuticals is a GI-focused biotech company that generates stable profits from its blockbuster IBS-C therapy, LINZESS, while developing a pipeline…
$3.88 (as of 2026-07-22) · market cap $637M
-
ONCOLOGY INSTITUTE INCTOIHealth Care
The Oncology Institute is a value-based oncology care provider that manages outpatient cancer treatment through a national network of clinics and integrated…
$5.29 (as of 2026-07-22) · market cap $529M
-
ALPHA TEKNOVA INCTKNOHealth Care
Alpha Teknova is a specialized manufacturer of essential reagents and custom chemical solutions that accelerate the development and production of…
$5.24 (as of 2026-07-22) · market cap $281M
-
NAUTILUS BIOTECHNOLGY INCNAUTHealth Care
A pre-commercial proteomics platform company developing Iterative Mapping technology to enable single-molecule protein counting for comprehensive, reproducible…
$1.70 (as of 2026-07-22) · market cap $216M
-
VIRIDIAN THERAPEUTICS ORS INCVRDNHealth Care
Viridian is a clinical-stage biopharmaceutical company developing potentially differentiated monoclonal antibody therapies for thyroid eye disease and…
$19.17 (as of 2026-07-22) · market cap $2.1B
Not quite? Describe exactly what you want →
Peers are Seaport Therapeutics, Inc.'s closest public companies by shared sub-industry, sector and business themes. See the full profile: Seaport Therapeutics, Inc. (SPTX).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.